within Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH11_Delgocitinib;

model Delgocitinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 0,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Delgocitinib</td></tr><tr><td>ATC code:</td><td>D11AH11</td></tr><td>route:</td><td>topical</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor indicated for the treatment of atopic dermatitis. It inhibits JAK1, JAK2, JAK3, and TYK2 and is approved as a topical ointment in some countries including Japan and the EU. Delgocitinib modulates immune response and inflammation associated with dermatological conditions.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic model parameters are available for topical delgocitinib. Limited data indicates minimal systemic absorption following topical administration in adults with atopic dermatitis.</p><h4>References</h4><ol><li><p>Nakagawa, H, et al., &amp; Ninomiya, N (2018). Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. <i>The Journal of dermatology</i> 45(6) 701–709. DOI:<a href=\"https://doi.org/10.1111/1346-8138.14322\">10.1111/1346-8138.14322</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29665062/\">https://pubmed.ncbi.nlm.nih.gov/29665062</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D11AH11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Delgocitinib;
